- Home
- CGC vs ZURA Comparison
CGC vs ZURA Comparison
Compare CGC & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | ZURA |
|---|---|---|
| Founded | N/A | 2022 |
| Country | Canada | United States |
| Employees | N/A | 30 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 435.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGC | ZURA |
|---|---|---|
| Price | $1.07 | $6.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | ★ 8.2M | 461.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,759,000.00 | N/A |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.99 |
| 52 Week High | $2.38 | $7.25 |
Technical Indicators
Market Signals| Indicator | CGC | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 60.83 |
| Support Level | $1.01 | $5.62 |
| Resistance Level | $1.24 | N/A |
| Average True Range (ATR) | 0.04 | 0.49 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 18.42 | 78.80 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.